Navigation Links
Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
Date:7/10/2008

ANTONY, France, July 10 /PRNewswire-FirstCall/ --

- 1st Half-Year Sales Up 16%

- Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal to)12%

EUR millions 2006 2007 07/06 2008 08/07

EURM %Sales EURM %Sales % EURM %Sales %

change change

Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15

Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20

Other markets 1.2 4 1.3 4 15 2.0 5 47

SLIT 21.8 76 25.1 77 15 30.4 80 21

SCIT 5.4 19 5.6 18 5 6.1 16 7

Other products 1.5 5 1.5 5 (0) 1.6 4 4

Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18

Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14

Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18

Other markets 2.4 4 2.5 3 5 3.7 4 46

SLIT 49.4 77 59.7 80 21 71.3 82 19

SCIT 11.6 18 11.8 16 2 12.3 14 4

Other products 3.2 5 3.2 4 3 3.4 4 6

Total H1 sales 64.2 100 74.8 100 17 87.0 100 16

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

2008 second quarter sales recorded strong growth in all markets (+18% vs +13% in 2007). Eastern European markets and other markets outside Europe made a significant contribution to this growth. The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared to the first half 2007, when growth was already particularly strong (+ 17%). This good performance has enabled the Group to revise its sales growth guidance upwards to growth of at least 12% in 2008 (vs (greater than or equal to)10% previously), boosted by the growing success of the sublingual route, in which Stallergenes continues to strengthen its leadership.

The commercial launch of ORALAIR(R) Grasses for adults will take place in Germany in the next few weeks, following the grant, on 24 June 2008, of the marketing authorisation. The request for a paediatric extension of ORALAIR(R) Grasses has been filed with the Paul Ehrlich Institute. The application for clinical studies for ORALAIR(R) Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a strong level of activity and will show a marked improvement compared to 2007. These results will be released on 27 August 2008.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatment, Stallergenes devotes 16% of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and

is part of the sample composing the SBF 120 index.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP

Additional information is available on http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
2. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
3. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
4. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
5. Hoviones Sales Grow 11%
6. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
7. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
8. Increasing Sales Productivity Through Superior Sales Force Performance Management
9. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
10. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
11. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... PITTSBURGH , Dec. 8, 2016  The Board ... (PLSG), Western Pennsylvania,s only ... in leadership. In accordance with the succession plan developed ... several years, effective today, James (Jim) F. Jordan ... Executive Officer, succeeding John W. Manzetti , who ...
(Date:12/8/2016)... ... December 08, 2016 , ... From ... innovation is taking over sports. On Thursday, December 15th a panel of entrepreneurs, ... disrupting the playing field at a Smart Talk session. Smart Talk will run ...
(Date:12/8/2016)... Eurofins announces the appointment of Sean Murray , National Division ... Mr. Murray will bring valuable expertise to the ... leading international business teams. As the National Division Leader, he will ... status as the global leader in bio-analytical testing services. ... , , ...
(Date:12/8/2016)... England , December 8, 2016 ... has expanded its customisable SureSeqâ„¢ NGS panel range with the ... allowing fast and cost-effective study of variants in familial hypercholesterolemia ... number variation (CNV) detection on a single small panel and ... hotspot content. This includes all exons for LDLR , ...
Breaking Biology Technology:
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
Breaking Biology News(10 mins):